GlassScriptPhysician profile
Shivi Jain
NPI 1841529625
$109,667.05
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $6,939 · 2021: $9,882 · 2022: $21K · 2023: $30K · 2024: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $16K · Food and Beverage: $689 · Travel and Lodging: $315 · Education: $1.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,135.00 |
| Consulting Fee | $15,851.00 |
| Food and Beverage | $688.89 |
| Travel and Lodging | $315.25 |
| Education | $1.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36,861.87 | 2019-2024 | |
| Genzyme Corporation | $27,447.86 | 2020-2023 | |
| Sobi, INC | $19,067.46 | 2023-2024 | |
| Global Blood Therapeutics, INC. | $8,105.00 | 2021-2022 | |
| Argenx US, INC. | $7,716.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $4,705.00 | 2023 | |
| Bioverativ Therapeutics INC. | $3,038.00 | 2020 | |
| Dova Pharmaceuticals | $2,500.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $147.06 | 2024 | Darzalex, Carvykti, Tecvayli |
| Abbvie INC. | $78.47 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivi Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.